JW Holdings to actively target Brazilian and Indian markets
JW Holdings to actively target Brazilian and Indian markets
  • Jung Se-jin
  • 승인 2018.05.24 10:01
  • 댓글 0
이 기사를 공유합니다

JW Holdings announced on May 23th that it will join forces with Brazilian and Indian pharmaceutical companies to launch the ‘Phamerging Market’ in the emerging pharmaceutical market. JW Holdings has signed an export contract with SIF PARTICIPACOE in Brazil and AlnicheLifescience in India to supply finished drugs including triple chamber comprehensive nutritional supplements. 
Through this contract, JW Holdings has secured a bridgehead to target Brazil and India markets. 

‘SIF PARTICIPACOE’ is a pharmaceutical distributor holding company based in Annapolis, central Brazil. With full support from the Brazilian central government, it is leading the medicines industry in central Brazil. 

‘AlnicheLifescience’ is a specialized drug marketing company with 605 or more annual growth rate, which has gained competitiveness in specialized hospitals such as cancer centers and recreational hospitals as well as in areas such as nephrology, digestive medicine, and neurosurgery. 

JW Holdings will supply six types of finished medicines to Brazil’s ‘SIF PARTICIPACOE’, including the triple chamber general drub solutions ‘Combi Flex Lipid’ and ‘Combi Flex M Citi’, and also a hair loss and benign prostatic hyperplasia treatment ‘Finasteride’. India’s ‘AlnicheLifescience’ will export four types of triple chamber comprehensive nutritional fluid supplements.

The size of the export is confidential, according to the agreement. The contract period is five years from the first export date for each country and has been agreed to automatically be extended one year if the contract is successfully completed. 

As a result, JW Holdings is expected to export its medicines to the Brazilian and Indian markets on a stable basis every year through its ‘SIF PARTICIPACOE’ and ‘AlnicheLifescience’ Savings. 

 “Brazil and India are valued as potential markets for growth in the pharmaceutical industry. Through this export contract, HW has been recognized for its excellent product and price competitiveness, so we will actively pursue global emerging markets,” said Han Sung-kwon, CEO of JW Holdings.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트